Perhexiline is a carnitine palmitoyltransferase 1 (CPT1) and CPT2 inhibitor that was originally developed as an anti-anginal drug in the 1970s.{28039,28040,28041} It inhibits rat heart and liver CPT1 (IC50 = 77 and 148 µM, respectively) and rat heart CPT2 (IC50 = 79 µM).{28039,28040} Inhibition of CPT reduces uptake of long-chain fatty acids into the mitochondria, thereby shifting cellular metabolism from β-oxidation to glycolysis. Perhexilin inhibits mTORC1 signaling at 10 µM and induces autophagy ~7-fold at a concentration of 10 µM in MCF-7 cells.{17472}
产品描述
A CPT1 and CPT2 inhibitor that inhibits rat heart and liver CPT1 (IC50 = 77 and 148 µM, respectively), and rat heart CPT2 (IC50 = 79 µM); inhibits mTORC1 signaling and induces autophagy in MCF-7 cells at low µM levels
